BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

-New Technology Optimizes Plasma Collection Resulting in Efficiency Gains

-Helps Strengthen Plasma Supply Used to Produce Lifesaving and Life-Sustaining Medicines

BANNOCKBURN, Ill.--(BUSINESS WIRE)-- BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025.

The new Adaptive Nomogram technology leverages a plasma donor’s unique body attributes, resulting in a more personalized plasma donation and a potential increase in the average amount of plasma collected. Three BioLife plasma donation centers participated in Fresenius Kabi’s clinical trial to provide data for the U.S. FDA’s premarket review of the new technology. The data collected by BioLife during the clinical trial successfully demonstrated a ~11.5% increase in plasma collected on average per donor with the Aurora Xi Plasmapheresis System. Participation in the clinical trial enabled a more rapid launch plan for BioLife.

“We're the first company to introduce this new Adaptive Nomogram technology in our plasma donation centers, which is a demonstration of our commitment to investing in the latest technology to increase operational efficiency while maintaining the safety of our plasma donors,” said Hema Tallman, SVP and Global Head of BioLife Plasma Services. “This rollout will also continue helping us strengthen our plasma supply and provide people in need with the life-sustaining and lifesaving medicines that Takeda produces from plasma.”

“Fresenius Kabi is pleased to see the implementation of our Adaptive Nomogram at BioLife locations in the U.S. and believe it can play a key role in supporting plasma centers and the critical therapies they provide to patients,” said Dr. Christian Hauer, President, MedTech at Fresenius Kabi. “Such innovation is aimed at advancing efficiency and sustainability of plasma collection for customers by leveraging donor data to deliver one of the most personalized and optimized plasma collection processes available today."

With the addition of Fresenius Kabi’s Adaptive Nomogram and the already deployed Haemonetics Persona Nomogram, BioLife anticipates having new personalized nomograms rolled out to 100% of its plasma donation centers by end of March 2026.

About BioLife Plasma Services

BioLife Plasma Services is a trusted leader in the collection of high-quality plasma required to produce lifesaving and life-sustaining medicines for hundreds of thousands of people with rare and serious health conditions and in critical care settings. Plasma donations from more than 270 BioLife centers in the United States and Europe are essential to Takeda developing more than 20 approved brands of medicine made from plasma. BioLife Plasma Services is part of Takeda(TSE:4502/NYSE:TAK), a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. For more information, visit BioLifePlasma.com.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250505699828/en/

Media Contacts:

BioLife Plasma Services Media Relations

biolife.media.relations@takeda.com

Source: Takeda Pharmaceutical Company Limited